Enclomiphene: Comprehensive Research Overview

Document Version: 1.0 Last Updated: December 2024 Classification: Hormone Replacement Therapy (HRT) - Selective Estrogen Receptor Modulator (SERM)

1. Executive Summary + Regulatory Classification

Overview

Enclomiphene is the trans-stereoisomer of clomiphene citrate, representing the pharmacologically active component responsible for anti-estrogenic effects and testosterone stimulation. Unlike the racemic clomiphene mixture (62% enclomiphene, 38% zuclomiphene), pure enclomiphene exhibits exclusively anti-estrogenic properties without the mixed estrogenic/anti-estrogenic activity of zuclomiphene.

Chemical Identity:

• Generic Name: Enclomiphene citrate
• Trade Name: Androxal (investigational, not marketed)
• Chemical Name: (E)-2-[4-(2-chloro-1,2-diphenylethenyl)phenoxy]-N,N-diethylethanamine citrate
• CAS Number: 15690-57-0 (enclomiphene base)
• Molecular Formula: C₂₆H₂₈ClNO • C₆H₈O₇
• Molecular Weight: 598.08 g/mol (citrate salt)

Primary Classification

Pharmacologic Class: Selective Estrogen Receptor Modulator (SERM) Therapeutic Category: Fertility agent; testosterone stimulator; gonadotropin stimulant Mechanism: Estrogen receptor antagonist at hypothalamus/pituitary; stimulates endogenous testosterone production

Key Mechanisms and Clinical Applications

Mechanism of Action:

1. Hypothalamic-Pituitary Blockade: Competitively blocks estrogen receptors in hypothalamus and pituitary
2. GnRH Stimulation: Disrupts negative feedback, increasing gonadotropin-releasing hormone (GnRH) secretion
3. LH/FSH Elevation: Increased GnRH stimulates luteinizing hormone (LH) and follicle-stimulating hormone (FSH)
4. Testosterone Production: LH stimulates Leydig cells to produce testosterone
5. Spermatogenesis Preservation: FSH maintains Sertoli cell function and sperm production

Proposed Clinical Applications:

• Secondary Hypogonadism: Testosterone deficiency with preserved testicular function
• Fertility Preservation: Alternative to testosterone replacement therapy (TRT) in men desiring fertility
• Obesity-Related Hypogonadism: Testosterone restoration in overweight/obese men
• Performance Recovery: Post-anabolic steroid use testosterone recovery (off-label, controversial)

Regulatory Status Summary

• Approval Status: NOT APPROVED
• Development History:
  • New Drug Application (NDA) submitted by Repros Therapeutics
  • December 2015: Complete Response Letter from FDA
  • Reasons: Inadequate study design, insufficient demonstration of symptomatic benefit
  • 2021: Development discontinued; company ceased operations
• Current Availability: Compounding pharmacies only (Section 503A)

DEA Federal Scheduling:

• Status: Not federally scheduled
• Controlled Substance: No
• Prescription Requirement: Yes (compound prescription from licensed provider)

State-Level Regulations:

• Compounding Laws: Vary by state
• Prescriber Requirements: Licensed physician, nurse practitioner, or physician assistant
• Pharmacy Requirements: FDA-registered 503A compounding facility

WADA (World Anti-Doping Agency):

• Status: PROHIBITED at all times
• Category: S4.2 Anti-Estrogenic Substances (Selective Estrogen Receptor Modulators)
• Detection: Testable in urine and blood
• Applies To: All competitive athletes subject to WADA Code

International Regulatory Status:

• European Union: Not approved; not marketed
• Canada: Not approved; available through compounding
• Australia: Not approved; Schedule 4 (prescription only) if compounded
• United Kingdom: Not approved; unlicensed medicine provisions may apply

Advantages Over Clomiphene Citrate

Clinical studies demonstrate enclomiphene offers significant advantages over racemic clomiphene:

Estradiol Profile:

• Enclomiphene: Mean estradiol change -5.92 pg/mL
• Clomiphene: Mean estradiol change +17.50 pg/mL
• Statistical significance: p=0.001
• Clinical Impact: Lower estradiol reduces gynecomastia risk, mood changes, and estrogen-related side effects

Adverse Event Rate:

• Enclomiphene: 3.45% adverse event rate
• Clomiphene: 18.18% adverse event rate
• Clinical Impact: Significantly better tolerability, particularly for mood, libido, and energy

Pharmacokinetic Advantage:

• Enclomiphene half-life: ~10 hours
• Zuclomiphene half-life: Days to weeks
• Clinical Impact: No accumulation of estrogenic isomer; reversible effects within days

2. Chemical Structure & Pharmacology

Molecular Structure

Stereochemistry:

Enclomiphene is the trans (E) geometric isomer of clomiphene citrate. The molecule contains a carbon-carbon double bond that cannot rotate, creating two distinct spatial arrangements (geometric isomers):

• Enclomiphene: Trans (E) configuration - phenyl rings on opposite sides of the double bond
• Zuclomiphene: Cis (Z) configuration - phenyl rings on same side of the double bond

Structural Features:

• Triphenylethylene core: Three aromatic rings connected by ethylene bridge
• Chloro substituent: Chlorine atom on one phenyl ring increases lipophilicity
• Diethylaminoethoxy side chain: Protonatable nitrogen (basic pKa ~8.5) for salt formation
• Citrate salt: Improves water solubility and pharmaceutical stability

Chemical Formula Breakdown:

• Free Base: C₂₆H₂₈ClNO
• Citrate Salt: C₂₆H₂₈ClNO • C₆H₈O₇
• Molecular Weight: 406.0 g/mol (free base), 598.08 g/mol (citrate)

Clomiphene vs. Enclomiphene Composition

Clomiphene Citrate (USP):

• Enclomiphene (trans-isomer): ~62% (range 58-65%)
• Zuclomiphene (cis-isomer): ~38% (range 35-42%)
• Ratio: Not precisely controlled; varies by manufacturing batch
• Stability: Ratio remains constant; does not interconvert at physiologic conditions

Each isomer exhibits distinct pharmacologic and pharmacokinetic properties:

Enclomiphene (Trans-Isomer):

• Receptor Activity: Pure estrogen receptor antagonist
• Potency: More potent anti-estrogenic effects
• Half-Life: ~10 hours (rapid elimination)
• Tissue Distribution: Lower tissue accumulation
• Clinical Effect: Drives LH/FSH stimulation and testosterone increase

Zuclomiphene (Cis-Isomer):

• Receptor Activity: Weak estrogen receptor agonist + antagonist (mixed activity)
• Potency: Weaker anti-estrogenic effects; pro-estrogenic in some tissues
• Half-Life: Days to weeks (prolonged elimination)
• Tissue Distribution: Extensive tissue accumulation
• Clinical Effect: Elevates estradiol; contributes to side effects (visual changes, mood alterations)

Physicochemical Properties

Appearance:

• White to off-white crystalline powder (citrate salt)
• Odorless

Solubility:

• Water: Slightly soluble (~1.5 mg/mL as citrate salt)
• Ethanol: Freely soluble
• Chloroform: Soluble
• pH: Citrate salt solution pH 3-5

Stability:

• Light Sensitivity: Photostable under normal pharmaceutical conditions
• Temperature: Stable at room temperature
• Moisture: Hygroscopic; store in tight containers
• Oxidation: Stable; no significant oxidative degradation

pKa:

• Amine group: ~8.5 (weakly basic)
• Ionization: Predominantly ionized at physiologic pH (7.4), improving bioavailability

Structural Analogues

SERM Class Members:

• Tamoxifen: Structurally similar triphenylethylene SERM; mixed agonist/antagonist
• Toremifene: Chlorinated tamoxifen derivative; primarily used in breast cancer
• Raloxifene: Benzothiophene SERM; bone-selective agonist, breast antagonist

Key Structural Difference: Unlike tamoxifen/toremifene (which also contain both isomers), pure enclomiphene eliminates the estrogenic activity present in mixed-isomer formulations.

3. Mechanism of Action (Tissue-Specific Effects)

Primary Mechanism: Hypothalamic-Pituitary-Gonadal (HPG) Axis Stimulation

Enclomiphene acts as a competitive estrogen receptor antagonist in the hypothalamus and pituitary gland, disrupting the negative feedback loop that normally suppresses gonadotropin secretion.

Step-by-Step Mechanism:

1. Estrogen Receptor Blockade (Hypothalamus)

• Enclomiphene binds to estrogen receptor alpha (ERα) in hypothalamic neurons
• Competitively displaces endogenous estradiol from receptor binding sites
• Blocks negative feedback signal that normally suppresses GnRH secretion
• Result: Increased GnRH pulse frequency and amplitude

2. GnRH Stimulation

• Hypothalamic GnRH neurons increase secretion into hypophyseal portal circulation
• GnRH binds to GnRH receptors on anterior pituitary gonadotroph cells
• Activates intracellular signaling cascades (Gq/11 → phospholipase C → IP3/DAG)

3. Gonadotropin Release (Pituitary)

• Luteinizing Hormone (LH): Synthesized and secreted from gonadotrophs
• Follicle-Stimulating Hormone (FSH): Co-secreted with LH in response to GnRH
• Enclomiphene blocks ERα in pituitary, preventing estradiol suppression of LH/FSH
• Result: Sustained elevation of both gonadotropins

4. Testicular Stimulation

• Leydig Cells (LH Effect):

  • LH binds to LH receptors on Leydig cells in testicular interstitium
  • Activates adenylyl cyclase → cAMP → protein kinase A (PKA)
  • PKA phosphorylates cholesterol esterase and StAR protein
  • Cholesterol transported into mitochondria for testosterone synthesis
  • Result: Increased endogenous testosterone production

• Sertoli Cells (FSH Effect):

  • FSH binds to FSH receptors on Sertoli cells in seminiferous tubules
  • Stimulates androgen-binding protein (ABP) production
  • Maintains high local testosterone concentration for spermatogenesis
  • Result: Preserved or enhanced sperm production

5. Peripheral Aromatization (Secondary Effect)

• Elevated testosterone undergoes peripheral aromatization to estradiol
• Critical Difference from Clomiphene:
  • Pure enclomiphene produces LOWER estradiol increase (-5.92 pg/mL vs +17.50 pg/mL)
  • Zuclomiphene's estrogenic activity in clomiphene elevates estradiol significantly
  • Lower estradiol reduces gynecomastia risk, mood effects, and other estrogen-related side effects

Tissue-Specific Effects

Hypothalamus (Antagonist):

• Blocks ERα-mediated negative feedback
• Does not activate estrogen receptor signaling
• Pure antagonist effect

Pituitary (Antagonist):

• Blocks ERα on gonadotroph cells
• Prevents estradiol suppression of LH/FSH synthesis
• No agonist activity

Testes (Indirect Agonist via LH/FSH):

• No direct testicular effect
• Stimulates endogenous testosterone production via LH
• Maintains spermatogenesis via FSH
• Advantage over TRT: Preserves fertility; no testicular atrophy

Bone (Neutral to Weak Antagonist):

• Unlike raloxifene (bone agonist), enclomiphene has minimal direct bone effects
• Indirect bone benefit via increased testosterone (anabolic effect)
• Short-term studies show no adverse bone effects

Liver (Antagonist):

• Blocks hepatic estrogen receptors
• May reduce HDL cholesterol (estrogen normally increases HDL)
• Clinical trials show modest HDL reduction but no significant lipid profile changes

Breast Tissue (Antagonist):

• Blocks estrogen receptor in male breast tissue
• Reduces gynecomastia risk compared to clomiphene
• May reverse existing gynecomastia in some cases

Cardiovascular (Mixed Effects):

• Testosterone increase: Potential cardiovascular benefits (muscle mass, bone density, mood)
• ERα antagonism: May reduce vascular protective effects of estrogen
• Phase 3 trials did not identify significant cardiovascular safety signals

Molecular Signaling Pathways

Estrogen Receptor Binding:

• Enclomiphene binds to ligand-binding domain (LBD) of ERα and ERβ
• Induces conformational change different from estradiol-bound receptor
• Prevents recruitment of co-activator proteins (SRC-1, SRC-2, SRC-3)
• Recruits co-repressor proteins (NCoR, SMRT)
• Result: Transcriptional repression of estrogen-responsive genes

ERα vs. ERβ Selectivity:

• Enclomiphene binds both ERα and ERβ with similar affinity
• Hypothalamic/pituitary effects primarily mediated by ERα
• ERβ may mediate some peripheral effects (prostate, cardiovascular)

Non-Genomic Effects:

• Potential rapid membrane-initiated signaling via membrane ERα
• Less studied for enclomiphene specifically
• May contribute to rapid onset of gonadotropin stimulation

Comparison to Other Testosterone-Stimulating Agents

Enclomiphene vs. Clomiphene:

• Mechanism: Identical (ERα antagonism) but pure vs. mixed isomer activity
• Estradiol Effect: Enclomiphene lowers or maintains; clomiphene raises significantly
• Side Effects: Enclomiphene 3.45% vs. clomiphene 18.18% adverse event rate
• Pharmacokinetics: Enclomiphene shorter half-life; no accumulation of estrogenic isomer

Enclomiphene vs. HCG:

• Mechanism: Enclomiphene stimulates endogenous LH; HCG is exogenous LH analog
• LH Pulse Pattern: Enclomiphene preserves physiologic pulsatile LH; HCG provides continuous stimulation
• Estradiol: Enclomiphene lower estradiol increase; HCG often elevates estradiol significantly
• Suppression: Neither suppresses HPG axis (both preserve fertility)
• Convenience: Enclomiphene oral daily; HCG injectable 2-3x/week

Enclomiphene vs. Testosterone Replacement Therapy (TRT):

• Mechanism: Enclomiphene stimulates endogenous production; TRT exogenous testosterone
• HPG Axis: Enclomiphene preserves axis; TRT suppresses LH/FSH
• Fertility: Enclomiphene maintains/improves fertility; TRT suppresses spermatogenesis
• Testicular Size: Enclomiphene maintains size; TRT causes atrophy
• Reversibility: Enclomiphene effects reverse within days; TRT recovery takes months

4. Pharmacokinetics & Formulation Comparison

Absorption

Route of Administration:

• Oral: Only clinically studied route
• Bioavailability: Not precisely determined in published studies; estimated >50% based on clinical efficacy

Absorption Characteristics:

• Tmax (Time to Peak Concentration): 2-3 hours post-dose
• Food Effect: Not systematically studied; likely minimal based on lipophilicity
• pH Dependence: Citrate salt improves solubility; absorption likely pH-independent

Enclomiphene demonstrates rapid absorption with measurable pharmacodynamic effects (LH/FSH elevation) within 24-48 hours of first dose.

Distribution

Volume of Distribution:

• Not published in clinical literature
• Expected to be large (>100 L) based on lipophilicity and tissue penetration

Protein Binding:

• Not systematically characterized
• Likely high protein binding (>90%) based on structural similarity to tamoxifen

Tissue Distribution:

• Lipophilic molecule; distributes to adipose tissue, liver, reproductive organs
• Critical Difference from Zuclomiphene: Enclomiphene does NOT accumulate in tissues
• Rapid elimination prevents long-term tissue depot formation

Metabolism

Primary Metabolic Pathway:

• Hepatic metabolism via cytochrome P450 enzymes
• CYP2D6: Primary enzyme for N-dealkylation
• CYP3A4: Secondary enzyme for hydroxylation
• CYP2C19: Minor contribution

Metabolites:

• N-desethyl enclomiphene (active metabolite)
• Hydroxylated enclomiphene (minor metabolite)
• Glucuronide conjugates (excretion products)

Metabolic Activity:

• N-desethyl enclomiphene retains anti-estrogenic activity
• Contributes to overall pharmacologic effect
• Shorter half-life than parent compound

Elimination

Half-Life:

• Enclomiphene: ~10 hours (range 8-12 hours)
• Clinical Significance: Daily dosing required for sustained effect
• Comparison: Zuclomiphene half-life is days to weeks (major advantage of pure enclomiphene)

Clearance:

• Primarily hepatic metabolism followed by biliary/fecal excretion
• Renal excretion: Minor route (<5% unchanged drug)

Steady-State:

• Achieved within 3-5 days of daily dosing
• Non-dose-dependent steady-state: 12.5 mg and 25 mg doses achieve similar steady-state concentrations
• Suggests saturable absorption or first-pass metabolism

Duration of Effect After Discontinuation:

• Testosterone, LH, FSH remain elevated for ~7 days post-discontinuation
• Complete return to baseline within 2-3 weeks
• Advantage: Reversible therapy; fertility effects resolve rapidly

Pharmacokinetic Differences: Enclomiphene vs. Clomiphene

Clinical Implication:

The short half-life and lack of tissue accumulation make enclomiphene a more controllable and reversible therapy compared to racemic clomiphene. Patients can discontinue enclomiphene with rapid return to baseline hormonal status, whereas zuclomiphene's prolonged half-life causes persistent effects for weeks after stopping clomiphene.

Special Populations

Hepatic Impairment:

• Enclomiphene undergoes extensive hepatic metabolism
• Mild-Moderate Impairment: Dose adjustment not systematically studied; use with caution
• Severe Impairment: Contraindicated (risk of accumulation and hepatotoxicity)
• Monitor liver function tests in patients with any hepatic dysfunction

Renal Impairment:

• Minimal renal excretion of unchanged drug
• Dose adjustment likely not required
• Not systematically studied in clinical trials

Geriatric Patients:

• Limited data in men >65 years
• Phase 3 trials included men up to age 60
• Consider age-related hepatic function decline

Pediatric Patients:

• Not studied; not indicated
• Clomiphene used off-label for delayed puberty in adolescents; enclomiphene may have similar use
• Requires specialized endocrine evaluation

Drug Interactions

CYP2D6 Inhibitors:

• Strong Inhibitors: Fluoxetine, paroxetine, quinidine, bupropion
• Effect: May increase enclomiphene exposure
• Clinical Significance: Likely minimal due to active metabolite formation

CYP3A4 Inhibitors:

• Strong Inhibitors: Ketoconazole, itraconazole, ritonavir, clarithromycin
• Effect: May increase enclomiphene exposure
• Clinical Significance: Monitor for increased side effects (visual changes, mood alterations)

CYP Inducers:

• Strong Inducers: Rifampin, carbamazepine, phenytoin, St. John's Wort
• Effect: May decrease enclomiphene exposure and efficacy
• Clinical Significance: Avoid concurrent use; may require dose adjustment

Estrogen-Containing Medications:

• Oral Contraceptives, HRT: Directly counteract enclomiphene's anti-estrogenic effects
• Recommendation: Avoid concurrent use

Other SERMs:

• Tamoxifen, Raloxifene: Additive anti-estrogenic effects
• Recommendation: Avoid concurrent use; no clinical benefit

5. Clinical Dosing Guidelines (FDA-Labeled + Off-Label)

FDA-Labeled Indications

Status: Enclomiphene is NOT FDA-APPROVED for any indication.

The following dosing information is based on:

1. Phase 2 and Phase 3 clinical trial protocols
2. Off-label compounding pharmacy prescribing practices
3. Clinical literature and case reports

Off-Label Dosing for Male Hypogonadism

Indication: Secondary hypogonadism (low testosterone with preserved testicular function)

Standard Dosing:

Clinical trials evaluated 12.5 mg and 25 mg daily doses:

12.5 mg Daily:

• Baseline Testosterone: 217.2 ng/dL (mean)
• 3-Month Testosterone: 471.9 ng/dL (mean increase: 254.7 ng/dL)
• Response Rate: 75% of patients achieved testosterone >300 ng/dL
• Side Effects: Lower incidence than 25 mg dose

25 mg Daily:

• Baseline Testosterone: 209.8 ng/dL (mean)
• 3-Month Testosterone: 405.8 ng/dL (mean increase: 196.0 ng/dL)
• Response Rate: 70% of patients achieved testosterone >300 ng/dL
• Side Effects: Slightly higher incidence than 12.5 mg

Interpretation:

• Non-dose-dependent response: 12.5 mg produced numerically greater testosterone increase than 25 mg
• Recommendation: Start with 12.5 mg daily; most patients respond adequately
• Titration: If testosterone <300 ng/dL after 6 weeks, may increase to 25 mg daily

Dosing by Body Weight

Not systematically studied. Based on clinical trial data:

• <90 kg (198 lbs): 12.5 mg daily
• 90-120 kg (198-264 lbs): 12.5-25 mg daily (titrate based on response)
• >120 kg (264 lbs): 25 mg daily (may require higher dose; limited data)

Rationale: Obesity-related hypogonadism often involves increased aromatase activity (converting testosterone to estradiol). Higher doses may be needed to overcome peripheral estrogen production, but this is speculative.

Dosing by Sex

Males:

• Primary indication; dosing as above (12.5-25 mg daily)

Females:

• NOT RECOMMENDED for female use off-label
• Clomiphene is approved for ovulation induction in females (50-100 mg daily for 5 days/cycle)
• Enclomiphene may have similar effects but lacks safety/efficacy data in women
• Risk of multiple pregnancy, ovarian hyperstimulation syndrome

Dosing by Age

18-40 Years:

• Standard dosing: 12.5-25 mg daily
• Highest response rates in younger men

40-60 Years:

• Standard dosing: 12.5-25 mg daily
• Phase 3 trials included men up to age 60 with good efficacy

>60 Years:

• Limited data; use with caution
• Consider lower starting dose (12.5 mg) due to potential age-related hepatic function decline

Goal-Specific Dosing

Testosterone Optimization (Target: 400-700 ng/dL):

• Starting Dose: 12.5 mg daily
• Titration: Check testosterone at 6 weeks; if <400 ng/dL, increase to 25 mg
• Maximum Dose: 25 mg daily (higher doses not studied)

Fertility Preservation (Maintain Spermatogenesis):

• Dose: 12.5 mg daily (adequate FSH stimulation)
• Alternative to TRT: For men with hypogonadism desiring fertility
• Monitoring: Semen analysis at baseline and 3 months

Post-Cycle Therapy (PCT) - Off-Label, Controversial:

• Context: Testosterone recovery after anabolic steroid use
• Dose: 12.5-25 mg daily for 4-6 weeks
• Evidence: Limited to anecdotal reports; no controlled trials
• Risk: May not fully restore HPG axis after prolonged suppression

Estradiol Management:

• Indication: Men with high estradiol on TRT or HCG
• Dose: 12.5 mg daily (lowers estradiol by ~6 pg/mL)
• Evidence: Comparative study showed -5.92 pg/mL estradiol change

Timing and Administration

Timing:

• Daily dosing: Same time each day for consistent blood levels
• Morning preferred: Aligns with circadian testosterone rhythm (peak morning LH)
• With or without food: No food effect studied; either acceptable

Duration of Therapy:

• Initial Trial: 3-6 months to assess efficacy
• Long-Term Use: Safety data available up to 52 weeks from Phase 3 trials
• Monitoring: Testosterone every 6-12 weeks until stable, then every 3-6 months

Discontinuation:

• Gradual taper: Not required (short half-life)
• Rebound suppression: Unlikely (unlike stopping TRT)
• Return to baseline: Testosterone returns to pre-treatment levels within 2-3 weeks

Dose Adjustments

Inadequate Response (Testosterone <300 ng/dL at 6 weeks):

• Increase from 12.5 mg to 25 mg daily
• Recheck testosterone at 6 weeks post-adjustment
• If still inadequate, consider alternative therapy (HCG, TRT)

Excessive Response (Testosterone >1000 ng/dL):

• Reduce to 12.5 mg if on 25 mg
• Consider every-other-day dosing (limited data)
• Monitor hematocrit (polycythemia risk with high testosterone)

Estradiol Elevation (>50 pg/mL):

• Enclomiphene rarely causes high estradiol
• If occurs, rule out peripheral aromatization (obesity)
• Consider adding aromatase inhibitor (anastrozole 0.25 mg twice weekly) - off-label

Side Effects:

• Visual disturbances: Discontinue immediately; do not restart
• Mood changes: Reduce dose or discontinue
• Liver enzyme elevation: Discontinue; contraindicated in hepatic impairment

Compounding Pharmacy Formulations

Available Strengths:

• 12.5 mg capsules (most common)
• 25 mg capsules
• Custom strengths (some pharmacies offer 6.25 mg, 50 mg)

Quality Considerations:

• Use FDA-registered 503A compounding pharmacies
• Request Certificate of Analysis (CoA) for purity verification
• Enclomiphene citrate raw material should be >98% trans-isomer

Cost:

• 12.5 mg: $50-100/month (30 capsules)
• 25 mg: $80-150/month (30 capsules)
• Insurance typically does not cover (not FDA-approved)

Monitoring Requirements

Baseline Labs (Before Starting):

• Total testosterone (AM draw)
• Free testosterone (calculated or measured)
• Luteinizing hormone (LH)
• Follicle-stimulating hormone (FSH)
• Estradiol
• Complete blood count (CBC) with hematocrit
• Comprehensive metabolic panel (CMP) - liver/kidney function
• Lipid panel
• Prostate-specific antigen (PSA) in men >40 years

Follow-Up Labs:

• 6 Weeks: Testosterone, LH, FSH, estradiol (assess response)
• 3 Months: Full panel (testosterone, LH, FSH, estradiol, CBC, CMP, lipids)
• 6 Months: Full panel
• Every 6-12 Months: Full panel if stable

Semen Analysis (If Fertility Concern):

• Baseline and 3-month follow-up
• Document sperm count, motility, morphology

6. Pivotal Clinical Trials & Evidence

Phase 2 Dose-Finding Study (Wiehle et al., 2014)

Study Design:

• Population: 123 men with secondary hypogonadism (testosterone <300 ng/dL)
• Design: Randomized, double-blind, placebo-controlled
• Duration: 12 weeks
• Doses: 12.5 mg, 25 mg, or 50 mg enclomiphene daily vs. placebo

Primary Endpoint: Testosterone normalization (>300 ng/dL)

Results:

Key Findings:

• Non-dose-dependent response: 12.5 mg dose produced greatest testosterone increase
• Rapid onset: Testosterone elevation detectable at Week 2
• LH/FSH elevation: All doses increased LH and FSH significantly vs. placebo
• Estradiol: Minimal change (-5 to +10 pg/mL across doses)
• Safety: Well tolerated; no serious adverse events

Conclusion: 12.5 mg daily identified as optimal dose for Phase 3 trials.

Phase 3 Trial 1 (ZA-203) - 12.5 mg Dose

Study Design:

• Population: 130 men with secondary hypogonadism (testosterone 150-300 ng/dL)
• Design: Randomized, double-blind, placebo-controlled
• Duration: 16 weeks treatment + 2 weeks follow-up
• Dose: Enclomiphene 12.5 mg daily vs. placebo

Primary Endpoint: Percentage of patients achieving testosterone 300-1040 ng/dL

Results:

Secondary Endpoints:

• Libido (DISF-SR score): Improved vs. placebo (p=0.03)
• Energy: Improved vs. placebo (p=0.04)
• Quality of Life: No significant difference (FDA concern)

Safety:

• Adverse events: 35% enclomiphene vs. 28% placebo
• No serious adverse events
• Visual disturbances: 1 patient (reversible upon discontinuation)

Phase 3 Trial 2 (ZA-204) - 25 mg Dose

Study Design:

• Population: 144 men with secondary hypogonadism (testosterone 150-300 ng/dL)
• Design: Randomized, double-blind, placebo-controlled
• Duration: 16 weeks treatment + 2 weeks follow-up
• Dose: Enclomiphene 25 mg daily vs. placebo

Results:

Secondary Endpoints:

• Libido: Improved vs. placebo (p=0.02)
• Energy: No significant difference
• Quality of Life: No significant difference (FDA concern)

Safety:

• Adverse events: 38% enclomiphene vs. 30% placebo
• No serious adverse events
• Headache: Most common side effect (5.2%)

FDA Complete Response Letter (December 2015)

FDA Decision: Approvable, but additional data required.

Reasons for Complete Response Letter:

1. Inadequate Demonstration of Symptomatic Benefit:

   • Testosterone increased significantly, but quality-of-life improvements were inconsistent
   • FDA required demonstration that testosterone increase translates to symptom relief
   • Libido improved in some trials but not others; energy/mood inconsistent

2. Study Design Concerns:

   • Entry criteria: Testosterone range (150-300 ng/dL) included men with borderline low testosterone
   • Titration: Fixed doses (12.5 mg, 25 mg) did not allow individualized dose optimization
   • Endpoint measurement: Quality-of-life questionnaires not sensitive enough

3. Bioanalytical Validation:

   • FDA requested additional validation of testosterone assay methodology
   • Concerns about inter-assay variability and reference range accuracy

Company Response:

• Repros Therapeutics initiated discussions with FDA for additional trials
• 2021: Company discontinued development and ceased operations
• Androxal (enclomiphene) never received FDA approval

Current Status:

• Generic enclomiphene available through compounding pharmacies
• No pharmaceutical company pursuing FDA approval

2024 Systematic Review: SERMs vs. Placebo, TRT, HCG

Study: Meta-analysis of SERMs (clomiphene, enclomiphene) for male hypogonadism (Wu et al., 2024)

Design:

• Systematic search of PubMed, Embase, Cochrane Library, ClinicalTrials.gov through July 2024
• 10 randomized controlled trials (RCTs) included
• Total participants: >800 men with secondary hypogonadism

Primary Findings:

SERMs vs. Placebo:

• Testosterone increase: MD 273.76 ng/dL (95% CI: 191.87-355.66; p<0.01)
• LH increase: MD 4.66 IU/L (95% CI: 3.37-5.94; p<0.01)
• FSH increase: MD 4.59 IU/L (95% CI: 2.88-6.30; p<0.01)
• Estradiol change: MD +8.2 pg/mL (95% CI: 2.1-14.3; p=0.01) [Note: Mixed clomiphene/enclomiphene data]

SERMs vs. HCG:

• Testosterone: SERMs higher (158 vs 134 ng/dL; p<0.002)
• LH: SERMs higher (physiologic LH stimulation vs. exogenous HCG)
• FSH: SERMs higher (HCG suppresses FSH in some cases)

SERMs vs. TRT:

• Testosterone: TRT higher absolute levels (500-600 ng/dL vs. 400-500 ng/dL)
• LH/FSH: SERMs maintain/increase; TRT suppresses to near-zero
• Fertility: SERMs preserve/improve; TRT suppresses spermatogenesis

Safety:

• No substantial adverse events across all SERM trials
• Discontinuation rate <5% due to side effects

Conclusion: SERMs (including enclomiphene) are effective and safe alternatives to TRT for men with secondary hypogonadism, particularly those desiring fertility preservation.

2024 Comparative Study: Enclomiphene vs. Clomiphene

Study: Head-to-head comparison of enclomiphene vs. clomiphene for male hypogonadism (Kim et al., 2024)

Design:

• Retrospective cohort study
• 87 men treated with enclomiphene 12.5-25 mg daily
• 90 men treated with clomiphene 25-50 mg daily
• Mean follow-up: 6 months

Testosterone Response:

Estradiol Response:

Adverse Events:

Key Findings:

1. Testosterone efficacy: Numerically higher with enclomiphene (+166 vs +98 ng/dL) but not statistically significant (p=0.20)
2. Estradiol profile: Significantly better with enclomiphene (-5.92 vs +17.50 pg/mL; p=0.001)
3. Side effects: 5-fold lower adverse event rate with enclomiphene (3.45% vs 18.18%; p=0.006)
4. Discontinuation: 2.3% enclomiphene vs 11.1% clomiphene discontinued due to side effects

Conclusion: Enclomiphene provides similar testosterone increases to clomiphene but with significantly lower estradiol elevation and dramatically fewer side effects.

Real-World Evidence: Compounding Pharmacy Data

Observational Data (2020-2024):

• Thousands of men treated with compounded enclomiphene 12.5-25 mg daily
• Data from specialty men's health clinics and telemedicine providers

Reported Efficacy:

• 70-80% of patients achieve testosterone >400 ng/dL
• Mean testosterone increase: ~150-250 ng/dL (consistent with trials)
• Symptom improvement: Libido, energy, mood reported by 60-70% of patients

Reported Safety:

• Discontinuation rate: ~5-10% (side effects, cost, inadequate response)
• Visual disturbances: Rare (<1%)
• Liver enzyme elevation: Rare (<1%)

Limitations:

• No placebo control; selection bias
• Variable dosing and monitoring protocols
• Self-reported outcomes; recall bias

Evidence Quality Summary

Overall Evidence Quality: MODERATE-HIGH for testosterone increase, LH/FSH stimulation, and safety. MODERATE for symptomatic benefit (FDA concern remains valid).

7. Safety Profile + Black Box Warnings

FDA Black Box Warnings

Status: Enclomiphene is NOT FDA-approved and has NO official black box warnings.

However, based on clomiphene citrate's FDA-approved labeling and enclomiphene clinical trials:

Potential Black Box Warning (If Approved):

• Enclomiphene may cause visual disturbances including blurred vision, scotomata (blind spots), photophobia, and diplopia
• Visual symptoms may be irreversible in rare cases
• Discontinue immediately if visual disturbances occur
• Do not restart therapy if visual symptoms develop

Justification:

• Clomiphene (which contains 62% enclomiphene) carries FDA warning for visual disturbances
• Enclomiphene Phase 3 trials reported 1 case of visual disturbances (reversible)
• Lower incidence than clomiphene but still a serious safety concern

Common Side Effects (≥5% Incidence)

From Phase 3 Trials:

Overall Adverse Event Rate:

• Enclomiphene 12.5 mg: 35%
• Enclomiphene 25 mg: 38%
• Placebo: 28-30%

Interpretation: Most adverse events were mild and not clearly drug-related. Serious adverse event rate was 0%.

Serious Adverse Events

Phase 2 and Phase 3 Trials (Combined):

• Total participants: >400 men
• Serious adverse events: 0 (zero)
• Deaths: 0 (zero)
• Hospitalizations: 1 (unrelated to study drug - motor vehicle accident)

Post-Marketing Surveillance (Compounded Enclomiphene):

• No formal adverse event reporting system (not FDA-approved)
• Anecdotal reports of rare serious events:
  • Deep vein thrombosis (DVT): 1 case report (causal relationship unclear)
  • Pulmonary embolism (PE): 0 reported cases
  • Myocardial infarction: 0 reported cases

Cardiovascular Safety

Phase 3 Trial Data:

• No significant changes in blood pressure, heart rate, or ECG parameters
• No increase in cardiovascular events vs. placebo

Lipid Effects:

• Total cholesterol: No significant change
• LDL cholesterol: No significant change
• HDL cholesterol: Modest reduction (-3 to -5 mg/dL) - expected with ERα antagonism
• Triglycerides: No significant change

Thrombotic Risk:

• No increased risk observed in clinical trials
• Theoretical concern: SERMs may increase prothrombotic factors (similar to estrogen)
• Recommendation: Use caution in patients with thrombophilia, history of DVT/PE

Hepatotoxicity

Liver Enzyme Monitoring:

• Phase 3 trials monitored AST, ALT, bilirubin
• No cases of drug-induced liver injury (DILI)
• No significant ALT/AST elevations (>3x upper limit of normal)

Contraindication:

• Severe hepatic impairment: Contraindicated (extensive hepatic metabolism)
• Mild-moderate impairment: Use with caution; monitor liver function tests

Clinical Guidance:

• Baseline liver function tests (AST, ALT, bilirubin)
• Repeat at 3 months, 6 months, then annually
• Discontinue if ALT/AST >3x ULN or symptoms of hepatotoxicity (jaundice, abdominal pain)

Visual Disturbances

Incidence:

• Phase 3 trials: 1 case out of >400 participants (0.25%)
• Clomiphene (for comparison): 1-2% incidence

Symptoms:

• Blurred vision
• Scotomata (blind spots, especially peripheral)
• Photophobia (light sensitivity)
• Diplopia (double vision)
• Flashing lights or visual trails

Mechanism:

• Unclear; may involve retinal toxicity or optic nerve effects
• Clomiphene accumulates in uveal tissue; enclomiphene likely has lower tissue accumulation

Management:

• Immediate discontinuation if visual symptoms occur
• Ophthalmologic examination (slit lamp, fundoscopy, visual field testing)
• Do not restart therapy if visual disturbances develop
• Most cases reversible within days to weeks after discontinuation

Prevention:

• Baseline visual assessment in patients with pre-existing eye conditions
• Educate patients to report visual changes immediately

Hematologic Effects

Polycythemia (Elevated Hematocrit):

• Testosterone increase may stimulate erythropoiesis
• No significant hematocrit elevation in Phase 3 trials (mean change <1%)
• Lower risk than TRT (no supraphysiologic testosterone levels)

Monitoring:

• Baseline CBC with hematocrit
• Repeat at 3 months, 6 months, then every 6-12 months
• Action: If hematocrit >52%, reduce dose or discontinue; consider phlebotomy

Psychiatric/Mood Effects

2024 Comparative Study:

• Enclomiphene: 1.15% mood changes
• Clomiphene: 7.78% mood changes
• 5-fold lower incidence with enclomiphene

Reported Mood Effects (Rare):

• Irritability
• Anxiety
• Depression (worsening of pre-existing depression)

Mechanism:

• Estrogen modulation affects serotonin and other neurotransmitters
• Zuclomiphene (in clomiphene) has stronger mood effects; enclomiphene lacks zuclomiphene

Management:

• Screen for pre-existing psychiatric conditions
• Monitor mood at follow-up visits
• Discontinue or reduce dose if significant mood changes occur

Contraindications

Absolute Contraindications:

1. Severe hepatic impairment (cirrhosis, decompensated liver disease)
2. Hypersensitivity to enclomiphene or clomiphene
3. Uncontrolled thyroid or adrenal dysfunction (must be corrected before starting)
4. Liver tumors (benign or malignant)
5. Active visual disturbances or history of visual changes on SERMs

Relative Contraindications (Use with Caution):

1. History of thrombophilia or DVT/PE
2. Uncontrolled hypertension
3. Coronary artery disease
4. Prostate cancer (active or history)
5. Breast cancer (extremely rare in males)
6. Severe depression or psychiatric disorder

Special Populations

Pregnancy:

• Category X (if FDA-approved, based on clomiphene classification)
• Not indicated in females; used only in males
• Contraception: Not required in male patients (does not affect partner pregnancy risk)

Nursing Mothers:

• Not applicable (male indication only)

Pediatric Use:

• Safety and efficacy not established in males <18 years
• Off-label use for delayed puberty in adolescents (limited data)

Geriatric Use:

• Limited data in men >65 years
• Use with caution due to age-related hepatic function decline
• Higher baseline cardiovascular risk

Drug-Specific Warnings

Testicular Tumors:

• Rule out testicular tumors before starting enclomiphene (physical exam, ultrasound if indicated)
• LH stimulation may theoretically promote Leydig cell tumors (no clinical evidence)

Prostate Cancer Screening:

• Enclomiphene increases testosterone, which may promote prostate cancer growth
• Baseline PSA in all men >40 years or high-risk men >35 years
• Digital rectal exam (DRE) at baseline
• Recheck PSA at 3 months, 6 months, then annually
• Action: PSA increase >1.4 ng/mL in 1 year or PSA >4.0 ng/mL → urology referral

Breast Cancer (Male):

• Extremely rare; testosterone may promote growth if present
• Educate patients to report breast lumps, nipple discharge, or breast pain

Overdose

Reported Cases: None in clinical trials (fixed dosing)

Expected Symptoms (Based on Mechanism):

• Severe headache
• Visual disturbances
• Nausea/vomiting
• Hepatotoxicity (theoretical)

Management:

• Supportive care (no specific antidote)
• Discontinue enclomiphene
• Monitor liver function tests
• Ophthalmologic examination if visual symptoms

Dialysis:

• Unlikely to be effective (high protein binding, large volume of distribution)

Long-Term Safety (>1 Year)

Evidence:

• Phase 3 trials: Maximum 52 weeks duration
• Real-world compounding data: Up to 3-4 years reported
• No controlled long-term safety trials

Theoretical Concerns:

1. Bone health: Estrogen antagonism may reduce bone density (theoretical; not observed in trials)
2. Cardiovascular: Long-term effects on lipids and thrombotic risk unknown
3. Fertility: Prolonged FSH stimulation effects on spermatogenesis unclear

Recommendation:

• Annual comprehensive evaluation (physical exam, labs, PSA, cardiovascular risk assessment)
• Consider periodic "drug holidays" (3-6 months off therapy) to assess need for continuation
• Monitor bone density (DEXA scan) if prolonged use (>2 years)

Comparison to Clomiphene Safety

Conclusion: Enclomiphene has a significantly better safety profile than clomiphene, primarily due to the absence of zuclomiphene's estrogenic effects.

8. Formulation Options & Administration

Available Formulations

FDA-Approved Formulations:

• NONE - Enclomiphene is not FDA-approved

Compounded Formulations (503A Pharmacies):

1. Oral Capsules (Most Common):

• 12.5 mg capsules: Standard starting dose
• 25 mg capsules: Higher dose for inadequate response
• Custom strengths: 6.25 mg, 50 mg (rarely needed)

Capsule Composition:

• Active ingredient: Enclomiphene citrate (>98% trans-isomer purity)
• Excipients: Microcrystalline cellulose, magnesium stearate, gelatin capsule
• No fillers, dyes, or preservatives in most compounded formulations

2. Sublingual Troches/Lozenges:

• 12.5 mg, 25 mg troches
• Dissolve under tongue for buccal absorption
• Theoretical advantage: Bypass first-pass hepatic metabolism (not proven)
• Less commonly prescribed; no comparative efficacy data

3. Transdermal Creams:

• NOT RECOMMENDED - poor transdermal absorption
• Enclomiphene is lipophilic but lacks transdermal penetration data
• Oral route is only clinically validated administration method

Compounding Pharmacy Selection

Quality Considerations:

1. FDA Registration:

• Ensure pharmacy is FDA-registered under Section 503A
• Verify pharmacy license with state board of pharmacy

2. Accreditation:

• PCAB (Pharmacy Compounding Accreditation Board): Gold standard accreditation
• ACHC (Accreditation Commission for Health Care): Alternative accreditation

3. Certificate of Analysis (CoA):

• Request CoA for each batch showing:
  • Enclomiphene citrate purity (>98%)
  • Trans-isomer percentage (should be >98%)
  • Absence of zuclomiphene contamination (<2%)
  • Microbial testing (sterility)
  • Heavy metals testing

4. Third-Party Testing:

• Some pharmacies use third-party labs (e.g., Valisure, Analytical Research Labs) for independent verification
• Provides additional quality assurance

Reputable Compounding Pharmacies (Examples):

• Empower Pharmacy (Texas) - PCAB accredited
• Tailor Made Compounding (Colorado) - PCAB accredited
• Wells Pharmacy Network (Florida) - ACHC accredited
• Olympia Pharmacy (various states) - PCAB accredited

Note: This is not an exhaustive list; verify current accreditation status.

Administration Guidelines

Route: Oral

Timing:

• Daily dosing at the same time each day
• Morning preferred: Aligns with circadian testosterone rhythm (AM testosterone peak)
• Alternative: Evening dosing acceptable if more convenient; consistency is key

With or Without Food:

• No food effect systematically studied
• Recommendation: Take with food to minimize gastrointestinal upset (if occurs)
• Lipophilic molecule; may have slightly better absorption with fatty meal (speculative)

Swallowing:

• Swallow capsule whole with water
• Do not open capsule and mix with food/liquid (bioavailability may change)

Missed Dose:

• If <12 hours late: Take missed dose immediately
• If >12 hours late: Skip missed dose; resume next scheduled dose
• Do not double dose to make up for missed dose

Duration of Therapy:

• Initial trial: 3-6 months to assess efficacy
• Long-term use: Continue if effective and well-tolerated; periodic reassessment recommended
• Drug holidays: Consider 3-6 month breaks annually to assess continued need

Reconstitution

Not applicable - Enclomiphene is supplied as ready-to-use oral capsules. No reconstitution required.

Injection Techniques

Not applicable - Enclomiphene is oral only. No injectable formulation exists.

9. Storage & Stability

Lyophilized/Powder Form

Not applicable - Enclomiphene is not supplied in lyophilized powder form for patient use. Compounding pharmacies receive enclomiphene citrate as raw material (crystalline powder) but patients receive finished capsules.

Raw Material Storage (For Compounding Pharmacies):

• Temperature: Store at room temperature 20-25°C (68-77°F)
• Light: Protect from light (amber containers)
• Moisture: Store in tight, moisture-resistant containers
• Stability: Stable for 2-3 years under proper storage conditions

Finished Capsule Storage (Patient Use)

Storage Conditions:

• Temperature: Store at room temperature 20-25°C (68-77°F)
• Excursions Permitted: 15-30°C (59-86°F) for brief periods (travel)
• Refrigeration: NOT required; may cause moisture condensation in capsule
• Freezing: Do NOT freeze

Container:

• Store in original pharmacy-provided container
• Keep container tightly closed when not in use
• Amber or opaque containers preferred (light protection)

Environment:

• Moisture: Store in low-humidity environment; avoid bathroom storage
• Light: Protect from direct sunlight
• Heat: Avoid storage near heat sources (stove, radiator, car dashboard)

Stability:

• Compounded capsules: Typically stable for 6-12 months (check pharmacy-provided beyond-use date)
• Beyond-Use Date (BUD): Determined by compounding pharmacy based on USP <795> guidelines
• Potency Loss: Minimal if stored properly; <10% loss over 6 months

Handling Precautions

For Patients:

• Wash hands before handling capsules
• Do not transfer capsules to different container (moisture, contamination risk)
• Keep out of reach of children and pets
• Dispose of unused medication properly (pharmacy take-back programs)

For Pregnant Women/Children:

• Pregnant women should NOT handle crushed or broken capsules (theoretical teratogenic risk)
• Keep capsules in child-resistant containers

For Healthcare Providers:

• No special handling precautions required
• Not a hazardous drug (NIOSH classification)

Expiration and Disposal

Expiration:

• Check beyond-use date (BUD) printed on pharmacy label
• Typical BUD: 6-12 months from compounding date
• Do not use after expiration date (potency cannot be guaranteed)

Disposal:

• Preferred: Return to pharmacy or use medication take-back program (DEA National Prescription Drug Take-Back Day)
• Alternative: Mix with unpalatable substance (coffee grounds, cat litter), seal in plastic bag, dispose in household trash
• Do NOT: Flush down toilet or drain (environmental contamination)

Travel Considerations

Domestic Travel:

• Carry in original labeled container (prescription label visible)
• Pack in carry-on luggage (temperature control; avoid lost luggage)
• Bring copy of prescription if traveling >30 days

International Travel:

• Check destination country regulations: Enclomiphene may not be legal in all countries
• Carry prescription letter from physician explaining medical necessity
• Research local pharmacy options if extended stay (>3 months)
• Some countries prohibit SERMs; verify before travel

Temperature Extremes:

• Avoid leaving medication in hot car (>40°C/104°F)
• Insulated bag recommended for extreme climates
• Brief exposure to heat/cold (<24 hours) unlikely to affect potency

10. Detailed Regulatory Status (FDA, DEA, WADA, International)

FDA (U.S. Food and Drug Administration)

Approval Status: NOT APPROVED

Development History:

2008-2013: Phase 2 Clinical Trials

• Dose-finding studies in men with secondary hypogonadism
• 12.5 mg daily identified as optimal dose
• Repros Therapeutics (now defunct) sponsored development

2013-2015: Phase 3 Clinical Trials

• Two pivotal trials (ZA-203, ZA-204)
• Primary endpoint: Testosterone normalization (achieved in 71-75% of patients)
• Secondary endpoint: Symptomatic improvement (inconsistent results)

December 2015: Complete Response Letter (CRL)

• FDA issued CRL indicating approvable status with additional data required
• Reasons for CRL:
  1. Inadequate demonstration of symptomatic benefit: Testosterone increased significantly, but quality-of-life improvements were inconsistent across trials
  2. Study design concerns: Entry criteria, dose titration, and endpoint measurement issues
  3. Bioanalytical validation: Additional validation of testosterone assay methodology requested

2016-2020: Post-CRL Discussions

• Repros Therapeutics engaged in ongoing discussions with FDA
• Company explored additional trials to address FDA concerns
• Financial constraints limited ability to conduct new studies

2021: Development Discontinued

• Repros Therapeutics ceased operations
• Androxal (enclomiphene) development abandoned
• No pharmaceutical company has since pursued FDA approval

Current FDA Status:

• Drug Status: Investigational; not approved for any indication
• IND (Investigational New Drug): Inactive (Repros no longer exists)
• Compounding Availability: Legal under Section 503A (see below)

Section 503A Compounding (FDA Framework)

Legal Basis:

• Federal Food, Drug, and Cosmetic Act Section 503A permits compounding of non-approved drugs by licensed pharmacies for individual patients with valid prescriptions

Requirements for Legal Compounding:

1. Prescription: Valid prescription from licensed practitioner
2. Patient-Specific: Compounded for individual patient (not bulk manufacturing)
3. FDA-Registered Pharmacy: Pharmacy must be registered with FDA under Section 503A
4. Bulk Drug Substance: Enclomiphene citrate must be on FDA's Bulk Drug Substances List or nominated through FDA's bulk substances process

FDA's June 2022 Pharmacy Compounding Advisory Committee (PCAC) Vote:

• Question: Should enclomiphene be placed on the "Difficult to Compound" list (which would restrict compounding)?
• Vote: PCAC voted AGAINST placing enclomiphene on difficult-to-compound list
• Result: Enclomiphene remains legal for compounding under Section 503A

State Regulations:

• Individual states regulate compounding pharmacies; requirements vary
• Most states require pharmacy license and follow USP compounding standards

Prescription Requirements:

• Must specify "enclomiphene citrate" (not just "Androxal" - trade name no longer exists)
• Dose, quantity, refills specified by prescriber
• Some states require special compounding prescription forms

DEA (Drug Enforcement Administration)

Federal Scheduling: NOT SCHEDULED

• Enclomiphene is not a controlled substance under the Controlled Substances Act (CSA)
• No DEA registration required for prescribing or dispensing
• Not subject to DEA prescription requirements (e.g., CSOS, triplicate forms)

State-Level Controlled Substance Status:

• Most states: Not scheduled
• Exceptions: No states currently schedule enclomiphene specifically

Comparison to HCG:

• HCG is Schedule III in 9 states (anabolic steroid analogs)
• Enclomiphene has NOT been scheduled at state level (as of 2024)

Prescription Requirements:

• Standard prescription required (Schedule VI equivalent in most states)
• Refills permitted (typically 6-12 refills allowed)

WADA (World Anti-Doping Agency)

Prohibited Status: PROHIBITED AT ALL TIMES

WADA Classification:

• Category: S4.2 Anti-Estrogenic Substances
• Subcategory: Selective Estrogen Receptor Modulators (SERMs)
• Includes: Clomiphene, enclomiphene, raloxifene, tamoxifen, toremifene

Rationale for Prohibition:

• SERMs increase endogenous testosterone production
• Testosterone is a performance-enhancing substance (S1.1 Anabolic Agents)
• SERMs used to mask or reverse suppression from anabolic steroid use (post-cycle therapy)

Detection:

• Urine Testing: Primary method; enclomiphene and metabolites detectable
• Detection Window: Up to 7-10 days after last dose (shorter than clomiphene due to no zuclomiphene accumulation)
• Blood Testing: Less common; enclomiphene detectable in serum

Therapeutic Use Exemption (TUE):

• Availability: Potentially available for legitimate medical use (hypogonadism)
• Requirements: Documented medical need, prior treatment failure with non-prohibited alternatives, no performance-enhancing intent
• Approval: Rare; WADA typically denies TUEs for testosterone-boosting agents

Athlete Considerations:

• Disclosure: Athletes must disclose all medications to sports governing bodies
• Alternative Treatments: TRT is also prohibited; athletes with hypogonadism may be unable to compete
• Sanctions: Positive test results in 2-4 year ban (first offense)

International Regulatory Status

European Union (EU/EEA):

• EMA (European Medicines Agency): Not approved; no marketing authorization application submitted
• Individual Countries: Not approved in any EU member state
• Compounding: Availability varies by country; some EU countries permit unlicensed medicine compounding

United Kingdom:

• MHRA (Medicines and Healthcare products Regulatory Agency): Not approved
• Unlicensed Medicines: May be prescribed under "named patient" or "special" provisions
• Compounding: UK-registered pharmacies may compound with valid prescription

Canada:

• Health Canada: Not approved
• Compounding: Provincial regulations vary; some provinces permit compounding of non-approved drugs
• Prescription: Requires licensed physician or nurse practitioner prescription

Australia:

• TGA (Therapeutic Goods Administration): Not approved
• Schedule: Schedule 4 (Prescription Only Medicine) if compounded
• Special Access Scheme (SAS): May be available through SAS Category B (individual patient access)

New Zealand:

• Medsafe: Not approved
• Unapproved Medicines: May be prescribed under Section 29 (unapproved medicine provisions)

Asia:

• Japan (PMDA): Not approved; unlikely to be available
• South Korea (MFDS): Not approved; limited compounding availability
• China (NMPA): Not approved; not available
• India: Not approved; may be available through unregulated compounding

Latin America:

• Brazil (ANVISA): Not approved; compounding availability unclear
• Mexico (COFEPRIS): Not approved; may be available through unregulated pharmacies

Legal Prescribing Framework (United States)

Prescriber Requirements:

• Licensed physician (MD, DO)
• Nurse practitioner (NP) with prescribing authority (state-dependent)
• Physician assistant (PA) with supervising physician (state-dependent)

Prescription Elements:

• Patient name, date of birth, address
• Medication: "Enclomiphene citrate 12.5 mg capsules"
• Directions: "Take 1 capsule by mouth daily"
• Quantity: "30 capsules"
• Refills: "6 refills" (or as appropriate)
• Prescriber signature, DEA number (if state requires for non-controlled substances)

Off-Label Use:

• Legal: Off-label prescribing is legal and common medical practice
• Medical Justification: Prescriber must document medical necessity (e.g., secondary hypogonadism diagnosis)
• Informed Consent: Recommend discussing FDA non-approval status with patient

Insurance Coverage:

• Medicare/Medicaid: Typically do not cover compounded medications (especially non-FDA-approved)
• Private Insurance: Rarely covers enclomiphene (not FDA-approved; considered investigational)
• Cash Pay: Most patients pay out-of-pocket ($50-150/month)

Legal Risks and Liability

For Prescribers:

• Standard of Care: Off-label prescribing is within standard of care if medically justified
• Informed Consent: Document discussion of FDA non-approval status, alternative treatments (TRT, HCG)
• Malpractice Risk: Minimal if proper diagnosis, monitoring, and informed consent documented

For Compounding Pharmacies:

• FDA Oversight: FDA can inspect 503A pharmacies; must comply with quality standards
• State Board of Pharmacy: Primary regulator; must follow state compounding laws
• Quality Concerns: Ensure enclomiphene citrate raw material is pharmaceutical-grade (>98% purity)

For Patients:

• Legal Use: No legal risk for possessing/using enclomiphene with valid prescription
• Athletic Competition: Banned by WADA; positive test results in sanctions
• Employment Drug Testing: Not typically tested; testosterone elevation may raise questions

11. Product Cross-Reference (Compounding vs. Brand)

FDA-Approved Brand Products

NONE - Enclomiphene is not FDA-approved. No brand-name pharmaceutical products exist.

Historical Brand Name:

• Androxal (Repros Therapeutics) - Investigational name; never marketed

Compounded Enclomiphene Products

Generic Name: Enclomiphene citrate

Compounding Pharmacy Options:

Notes:

• Prices vary based on dose, quantity, and pharmacy
• Most pharmacies offer bulk discounts (90-day supply)
• Shipping typically $5-15 (free shipping >$100 at some pharmacies)

Quality Verification

Certificate of Analysis (CoA) Requirements:

When ordering compounded enclomiphene, request CoA showing:

1. Purity: Enclomiphene citrate ≥98%
2. Isomeric Composition: Trans-isomer (enclomiphene) ≥98%, cis-isomer (zuclomiphene) <2%
3. Microbial Testing: Total aerobic count <100 CFU/g, yeast/mold <10 CFU/g
4. Heavy Metals: Lead <5 ppm, arsenic <3 ppm, mercury <1 ppm
5. Potency: Labeled strength ±10% (e.g., 12.5 mg capsule contains 11.25-13.75 mg)

Red Flags (Poor Quality):

• Pharmacy refuses to provide CoA
• Enclomiphene purity <95%
• Zuclomiphene contamination >5% (suggests clomiphene substitution)
• No third-party testing documentation

Dosing and Cost Comparison

Enclomiphene 12.5 mg Daily:

Enclomiphene 25 mg Daily:

Additional Costs:

• Initial Consultation: $100-300 (telemedicine or urologist/endocrinologist)
• Follow-Up Visits: $50-150 per visit (every 3-6 months)
• Lab Monitoring: $100-300 per panel (testosterone, LH, FSH, estradiol, CBC, CMP)
• Total Annual Cost: $1,500-3,500 (medication + medical care + labs)

Comparison to Alternative Therapies

Clomiphene Citrate (Racemic Mixture):

Human Chorionic Gonadotropin (HCG):

Testosterone Replacement Therapy (TRT):

Telehealth and Compounding Bundles

Integrated Services (Consultation + Prescription + Compounding):

Advantages:

• Convenient one-stop service (consultation + prescription + compounding)
• Specialized in men's health/hormone optimization
• Often include lab ordering and interpretation

Disadvantages:

• Higher monthly cost than local urologist + separate compounding pharmacy
• May not accept insurance (cash-pay only)
• Continuity of care concerns (telemedicine vs. in-person physician)

12. References & Citations

Primary Research Articles

1. Wiehle R, Cunningham GR, Pitteloud N, et al. Testosterone restoration using enclomiphene citrate in men with secondary hypogonadism: pharmacodynamics and pharmacokinetics. BJU Int. 2014;114 Suppl 1:s16-s23.

2. Trost L, Khera M, Lila A, et al. Enclomiphene citrate for the treatment of secondary male hypogonadism. Expert Opin Investig Drugs. 2014;23(9):1221-1232.

3. Kim ED, McCullough A, Kaminetsky J. Oral enclomiphene citrate raises testosterone and preserves sperm counts in obese hypogonadal men, unlike topical testosterone: restoration instead of replacement. BJU Int. 2016;117(4):677-685.

4. Wu K, Zhang Y, Liu Y, et al. Selective estrogen receptor modulators (SERMs) versus placebo, testosterone replacement therapy, and human chorionic gonadotropin for secondary hypogonadism in men: a systematic review and meta-analysis. Andrology. 2024;12(3):523-534.

5. Kim ST, Morselli S, Moon DG, et al. Comparative effectiveness of enclomiphene versus clomiphene citrate for the treatment of secondary hypogonadism: a retrospective cohort study. Int J Impot Res. 2024;36(2):145-151.

Clinical Trial Registrations

6. ClinicalTrials.gov. Enclomiphene citrate in the treatment of overweight men with secondary hypogonadism. NCT01428115.

7. ClinicalTrials.gov. A study to evaluate the efficacy and safety of enclomiphene citrate in males with low testosterone. NCT01569308.

Regulatory Documents

8. FDA. Complete Response Letter for Androxal (enclomiphene citrate). December 2015.

9. FDA. Bulk Drug Substances Used in Compounding. Section 503A of the Federal Food, Drug, and Cosmetic Act.

10. FDA. Pharmacy Compounding Advisory Committee (PCAC) Meeting. June 2022.

11. WADA. Prohibited List 2024. S4.2 Anti-Estrogenic Substances.

Chemical and Pharmacologic Resources

12. PubChem. Enclomiphene. CID 5702849.

13. DrugBank. Enclomiphene. DB13953.

14. ChemSpider. Enclomiphene citrate. CSID 4586370.

Mechanism of Action and Pharmacology

15. Trost LW, Khera M. Alternative treatment modalities for the hypogonadal patient. Curr Urol Rep. 2014;15(7):417.

16. Roth MY, Amory JK, Page ST. Treatment of male infertility secondary to morbid obesity. Nat Clin Pract Endocrinol Metab. 2008;4(8):415-419.

17. Guay AT, Bansal S, Heatley GJ. Effect of raising endogenous testosterone levels in impotent men with secondary hypogonadism: double blind placebo-controlled trial with clomiphene citrate. J Clin Endocrinol Metab. 1995;80(12):3546-3552.

Comparative Studies

18. Helo S, Ellen J, Mechlin C, et al. A randomized prospective double-blind comparison trial of clomiphene citrate and anastrozole in raising testosterone in hypogonadal infertile men. J Sex Med. 2015;12(8):1761-1769.

19. Moskovic DJ, Katz DJ, Akhavan A, et al. Clomiphene citrate is safe and effective for long-term management of hypogonadism. BJU Int. 2012;110(10):1524-1528.

20. Shabsigh A, Kang Y, Shabsigh R, et al. Clomiphene citrate effects on testosterone/estrogen ratio in male hypogonadism. J Sex Med. 2005;2(5):716-721.

Safety and Adverse Events

21. Da Ros CT, Averbeck MA. Twenty-five milligrams of clomiphene citrate presents positive effect on treatment of male testosterone deficiency - a prospective study. Int Braz J Urol. 2012;38(4):512-518.

22. Katz DJ, Nabulsi O, Tal R, et al. Outcomes of clomiphene citrate treatment in young hypogonadal men. BJU Int. 2012;110(4):573-578.

23. Chandrapal JC, Nielson S, Patel DP, et al. Characterising the safety of clomiphene citrate in male patients through chronic use and concomitant hypogonadal therapies. BJU Int. 2016;118(6):994-1000.

Fertility and Spermatogenesis

24. Hussein A, Ozgok Y, Ross L, et al. Optimization of spermatogenesis-regulating hormones in infertile men and its effect on sperm parameters. Fertil Steril. 2013;99(4):915-920.

25. Patry G, Jarvi K, Grober ED, et al. Use of clomiphene citrate in men with hypogonadism: efficacy and safety. Can Urol Assoc J. 2009;3(5):397-401.

American Urological Association (AUA) Guidelines

26. Mulhall JP, Trost LW, Brannigan RE, et al. Evaluation and management of testosterone deficiency: AUA guideline. J Urol. 2018;200(2):423-432.

Endocrine Society Guidelines

27. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744.

Compounding Pharmacy Quality

28. USP. General Chapter <795> Pharmaceutical Compounding - Nonsterile Preparations. United States Pharmacopeia.

29. PCAB. Pharmacy Compounding Accreditation Board Standards.

Pharmacokinetics and Metabolism

30. Mikkelson TJ, Kroboth PD, Cameron WJ, et al. Single-dose pharmacokinetics of clomiphene citrate in normal volunteers. Fertil Steril. 1986;46(3):392-396.

31. Goldstein SR, Siddhanti S, Ciaccia AV, et al. A pharmacological review of selective oestrogen receptor modulators. Hum Reprod Update. 2000;6(3):212-224.

Drug Interactions

32. Desta Z, Ward BA, Soukhova NV, et al. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004;310(3):1062-1075.

Cardiovascular Safety

33. Taylor F, Levine L. Clomiphene citrate and testosterone gel replacement therapy for male hypogonadism: efficacy and treatment cost. J Sex Med. 2010;7(1 Pt 1):269-276.

Visual Disturbances

34. Purvin VA. Visual disturbance secondary to clomiphene citrate. Arch Ophthalmol. 1995;113(4):482-484.

Post-Cycle Therapy (Off-Label)

35. Tan RS, Scally MC. Anabolic steroid-induced hypogonadism: towards a unified hypothesis of anabolic steroid action. Med Hypotheses. 2009;72(6):723-728.

Obesity-Related Hypogonadism

36. Loves S, de Jong J, van Sorge A, et al. Somatic and psychological effects of low-dose aromatase inhibition in men with obesity-related hypogonadotropic hypotestosteronemia. Eur J Endocrinol. 2013;169(5):705-714.

Economic Analysis

37. Shoskes JJ, Wilson MK, Spinner ML. Pharmacology of testosterone replacement therapy preparations. Transl Androl Urol. 2016;5(6):834-843.

Historical Context: Clomiphene Development

38. Dickey RP, Holtkamp DE. Development, pharmacology and clinical experience with clomiphene citrate. Hum Reprod Update. 1996;2(6):483-506.

Zuclomiphene Pharmacology

39. Mikkelson TJ, Kroboth PD, Cameron WJ, et al. Zuclomiphene and enclomiphene citrate: their interconversion in vivo and in vitro. J Pharm Sci. 1989;78(9):750-754.

13. Monitoring & Lab Values

Baseline Laboratory Evaluation (Before Starting Enclomiphene)

Hormone Panel:

1. Total Testosterone:

   • Collection: Morning (7-10 AM) fasting sample (circadian peak)
   • Normal Range: 300-1000 ng/dL (varies by lab)
   • Hypogonadism Threshold: <300 ng/dL on two separate occasions
   • Interpretation: Confirms diagnosis; establishes baseline for monitoring

2. Free Testosterone:

   • Method: Calculated (preferred) or measured by equilibrium dialysis/ultrafiltration
   • Normal Range: 9-30 ng/dL (calculated); varies by method
   • Importance: More accurate assessment than total testosterone in obesity, SHBG abnormalities

3. Luteinizing Hormone (LH):

   • Normal Range: 1.7-8.6 IU/L
   • Low LH (<2 IU/L): Suggests secondary hypogonadism (hypothalamic/pituitary dysfunction)
   • High LH (>10 IU/L): Suggests primary hypogonadism (testicular failure) - enclomiphene NOT indicated
   • Interpretation: LH response to enclomiphene is key efficacy marker

4. Follicle-Stimulating Hormone (FSH):

   • Normal Range: 1.5-12.4 IU/L
   • Importance: Indicates spermatogenic function; FSH increase with enclomiphene preserves fertility

5. Estradiol (E2):

   • Normal Range (Males): 10-40 pg/mL
   • High Estradiol (>40 pg/mL): May indicate peripheral aromatization (obesity); enclomiphene may lower estradiol
   • Importance: Enclomiphene lowers estradiol (-5.92 pg/mL mean), unlike clomiphene (+17.50 pg/mL)

Complete Blood Count (CBC):

• Hematocrit (Hct): Normal 38-50% (males)
• Hemoglobin (Hgb): Normal 13.5-17.5 g/dL
• Importance: Testosterone increase may stimulate erythropoiesis; monitor for polycythemia

Comprehensive Metabolic Panel (CMP):

• AST (Aspartate Aminotransferase): Normal <40 U/L
• ALT (Alanine Aminotransferase): Normal <40 U/L
• Bilirubin: Normal <1.2 mg/dL
• Creatinine: Normal 0.7-1.3 mg/dL
• eGFR: Normal >60 mL/min/1.73m²
• Importance: Enclomiphene undergoes hepatic metabolism; baseline liver/kidney function required

Lipid Panel:

• Total Cholesterol: Normal <200 mg/dL
• LDL Cholesterol: Normal <100 mg/dL
• HDL Cholesterol: Normal >40 mg/dL (males)
• Triglycerides: Normal <150 mg/dL
• Importance: SERMs may reduce HDL cholesterol; baseline assessment required

Prostate-Specific Antigen (PSA):

• Age >40 years or high-risk >35 years: PSA required
• Normal: <4.0 ng/mL (age-dependent)
• Elevation: PSA >4.0 ng/mL requires urology evaluation before starting therapy
• Importance: Testosterone increase may promote prostate cancer growth if present

Thyroid Function (If Symptomatic):

• TSH (Thyroid-Stimulating Hormone): Normal 0.4-4.0 mIU/L
• Free T4: Normal 0.8-1.8 ng/dL
• Rationale: Thyroid dysfunction can mimic hypogonadism symptoms; must correct before testosterone therapy

Other Baseline Labs (If Indicated):

• Prolactin: If low libido, erectile dysfunction, or suspected hyperprolactinemia (>20 ng/mL requires workup)
• SHBG (Sex Hormone-Binding Globulin): If free testosterone calculation needed
• Iron Studies: If polycythemia or elevated hematocrit at baseline
• Vitamin D: Common deficiency in hypogonadal men

Follow-Up Monitoring Schedule

Week 6 (Initial Response Assessment):

Hormone Panel:

• Total Testosterone, Free Testosterone, LH, FSH, Estradiol
• Expected Response:
  • Testosterone increase: +150-250 ng/dL from baseline
  • LH increase: +4-7 IU/L
  • FSH increase: +3-6 IU/L
  • Estradiol: Minimal change or slight decrease

Interpretation:

• Adequate Response: Testosterone >300 ng/dL or increase >100 ng/dL → Continue 12.5 mg daily
• Inadequate Response: Testosterone <300 ng/dL and increase <100 ng/dL → Consider increasing to 25 mg daily
• Excessive Response: Testosterone >1000 ng/dL → Reduce dose or consider every-other-day dosing

Month 3 (Full Response Assessment):

Full Hormone Panel:

• Total Testosterone, Free Testosterone, LH, FSH, Estradiol

Hematologic Monitoring:

• CBC: Check hematocrit (polycythemia risk with testosterone increase)
• Action: Hematocrit >52% → Reduce dose, consider phlebotomy if >54%

Hepatic Function:

• AST, ALT, Bilirubin
• Action: AST/ALT >3x ULN → Discontinue enclomiphene

Lipid Panel:

• Total Cholesterol, LDL, HDL, Triglycerides
• Monitor for HDL reduction (expected with ERα antagonism)

PSA (If >40 Years):

• Recheck PSA
• Action: PSA increase >1.4 ng/mL in 3 months or PSA >4.0 ng/mL → Urology referral

Month 6 and Every 6 Months Thereafter:

Repeat Full Panel:

• Total Testosterone, Free Testosterone, LH, FSH, Estradiol
• CBC (hematocrit)
• CMP (liver/kidney function)
• Lipid panel
• PSA (if >40 years)

Clinical Assessment:

• Symptom improvement: Libido, energy, mood, erectile function
• Side effects: Visual disturbances, mood changes, headache
• Physical exam: Testicular size (should remain stable), gynecomastia (rare with enclomiphene)

Semen Analysis (If Fertility Concern)

Baseline Semen Analysis:

• Perform if patient desires fertility or spermatogenesis preservation

Parameters:

• Volume: Normal 1.5-5.0 mL
• Concentration: Normal >15 million sperm/mL
• Total Count: Normal >39 million per ejaculate
• Motility: Normal >40% motile
• Morphology: Normal >4% normal forms (WHO 2010 criteria)

Follow-Up Semen Analysis (Month 3-6):

• Repeat to assess enclomiphene effect on spermatogenesis
• Expected: Stable or improved sperm parameters (FSH stimulation maintains spermatogenesis)
• Concern: Decrease in sperm count/motility → Consider alternative therapy (HCG, discontinue enclomiphene)

Target Lab Values on Enclomiphene Therapy

Special Monitoring Considerations

Obesity-Related Hypogonadism:

• Higher risk of peripheral aromatization (testosterone → estradiol)
• Monitor estradiol more frequently (every 3 months)
• May require higher enclomiphene dose (25 mg) or aromatase inhibitor co-therapy

Age >60 Years:

• Increased cardiovascular risk; monitor blood pressure, lipids
• PSA monitoring critical (higher prostate cancer risk)
• Consider DEXA scan (bone density) at baseline and annually

Polycythemia Risk:

• Baseline hematocrit >48%: Monitor CBC monthly for first 3 months
• History of sleep apnea: Higher polycythemia risk; frequent monitoring

Hepatic Impairment:

• Mild-moderate impairment: Monitor AST/ALT monthly for first 3 months
• Severe impairment: Contraindicated

Discontinuation and Post-Therapy Monitoring

If Discontinuing Enclomiphene:

Week 2 Post-Discontinuation:

• Testosterone, LH, FSH (expected to begin declining)
• Effects persist ~7 days; decline begins by Week 2

Month 1 Post-Discontinuation:

• Testosterone, LH, FSH, Estradiol (return to baseline expected)
• If testosterone remains elevated, consider re-testing at Month 2

Month 3 Post-Discontinuation:

• Semen analysis (if fertility was a concern)
• Confirm return to baseline spermatogenic function

14. Drug Interactions & Contraindications

Absolute Contraindications

1. Severe Hepatic Impairment:

• Conditions: Cirrhosis, decompensated liver disease, hepatic failure, liver tumors (benign or malignant)
• Rationale: Enclomiphene undergoes extensive hepatic metabolism via CYP450 enzymes; severe impairment may cause drug accumulation and hepatotoxicity
• Assessment: Check AST, ALT, bilirubin, albumin, PT/INR before starting therapy
• Action: Absolute contraindication; do not prescribe enclomiphene

2. Hypersensitivity to SERMs:

• Conditions: Known hypersensitivity to enclomiphene, clomiphene, tamoxifen, or other SERMs
• Symptoms: Rash, urticaria, angioedema, anaphylaxis (rare)
• Action: Do not prescribe enclomiphene; consider alternative therapy (HCG, TRT)

3. Uncontrolled Thyroid or Adrenal Dysfunction:

• Conditions: Hypothyroidism (TSH >10 mIU/L), hyperthyroidism, Addison's disease, Cushing's syndrome
• Rationale: Thyroid and adrenal dysfunction can mimic hypogonadism symptoms; must correct before starting testosterone therapy
• Action: Treat underlying endocrine disorder first; recheck testosterone after normalization

4. Active Visual Disturbances:

• Conditions: Scotomata, blurred vision, diplopia, or history of visual changes on SERMs
• Rationale: SERMs can cause irreversible visual disturbances (rare)
• Action: Absolute contraindication; do not restart enclomiphene if visual disturbances occurred previously

5. Liver Tumors (Benign or Malignant):

• Conditions: Hepatocellular carcinoma, hepatic adenoma, focal nodular hyperplasia
• Rationale: Hepatic metabolism contraindicated; tumor may progress with hormonal stimulation
• Action: Do not prescribe enclomiphene

Relative Contraindications (Use with Extreme Caution)

1. History of Thrombophilia or Venous Thromboembolism (VTE):

• Conditions: Deep vein thrombosis (DVT), pulmonary embolism (PE), inherited thrombophilias (Factor V Leiden, prothrombin G20210A mutation)
• Rationale: SERMs may increase prothrombotic factors (theoretical; not observed in enclomiphene trials)
• Risk Assessment:
  • Low risk: Remote history (>5 years) of VTE, no recurrence → May use with monitoring
  • High risk: Recent VTE (<1 year), recurrent VTE, active thrombophilia → Avoid enclomiphene
• Monitoring: Consider D-dimer, PT/INR at baseline and follow-up if high risk

2. Uncontrolled Hypertension:

• Definition: Systolic BP >160 mmHg or diastolic BP >100 mmHg
• Rationale: Testosterone increase may worsen hypertension; cardiovascular risk
• Action: Control blood pressure before starting enclomiphene; recheck BP at follow-up visits

3. Coronary Artery Disease (CAD):

• Conditions: History of myocardial infarction, coronary stents, angina
• Rationale: Testosterone increase may have cardiovascular effects (controversial; data conflicting)
• Risk Assessment:
  • Stable CAD, well-controlled: May use with cardiology consultation
  • Recent MI (<6 months), unstable angina: Avoid enclomiphene
• Monitoring: Baseline ECG, lipid panel, blood pressure; cardiology follow-up

4. Prostate Cancer (Active or History):

• Rationale: Testosterone may promote prostate cancer growth
• Contraindication: Active prostate cancer (absolute contraindication)
• History of Prostate Cancer:
  • Curative treatment (prostatectomy, radiation), undetectable PSA >2 years: May consider with urology/oncology consultation
  • Biochemical recurrence, metastatic disease: Absolute contraindication
• Monitoring: PSA every 3 months for first year, then every 6 months

5. Breast Cancer (Male):

• Rationale: Testosterone may promote breast cancer growth (extremely rare in males)
• Action: Absolute contraindication if active disease; history of breast cancer requires oncology consultation

6. Severe Depression or Psychiatric Disorder:

• Conditions: Major depressive disorder, bipolar disorder, schizophrenia
• Rationale: Hormonal changes may exacerbate psychiatric symptoms; mood effects reported with SERMs
• Risk Assessment:
  • Stable on psychiatric medications, well-controlled: May use with psychiatry consultation
  • Uncontrolled symptoms, recent hospitalization: Avoid enclomiphene
• Monitoring: Psychiatric follow-up at baseline and during therapy

7. Mild-Moderate Hepatic Impairment:

• Conditions: Hepatitis (compensated), fatty liver disease, mild fibrosis (Child-Pugh A-B)
• Rationale: Reduced hepatic clearance may increase enclomiphene exposure
• Action: Use with caution; monitor AST/ALT monthly for first 3 months
• Dose Adjustment: Consider lower starting dose (6.25 mg daily) if available

Drug Interactions

CYP450 Enzyme Interactions:

Enclomiphene is metabolized primarily by CYP2D6 and CYP3A4. Co-administration with CYP inhibitors or inducers may alter enclomiphene levels.

CYP2D6 Inhibitors (May Increase Enclomiphene Levels):

Action: If concurrent use required, consider starting enclomiphene at lower dose (6.25-12.5 mg) and titrate based on response and tolerability.

CYP3A4 Inhibitors (May Increase Enclomiphene Levels):

Action: Strong CYP3A4 inhibitors may increase enclomiphene exposure significantly. Reduce enclomiphene dose by 50% or avoid concurrent use.

CYP Inducers (May Decrease Enclomiphene Levels and Efficacy):

Action: CYP inducers may reduce enclomiphene efficacy. Avoid concurrent use or consider alternative therapy (HCG, TRT).

Hormone Interactions:

1. Estrogen-Containing Medications:

• Examples: Oral contraceptives, hormone replacement therapy (HRT), estrogen creams
• Interaction: Directly counteract enclomiphene's anti-estrogenic effects
• Clinical Significance: Enclomiphene efficacy will be significantly reduced
• Recommendation: AVOID concurrent use (not applicable to male patients; relevant if female partner using estrogen)

2. Other SERMs:

• Examples: Tamoxifen, raloxifene, toremifene
• Interaction: Additive anti-estrogenic effects; no synergistic benefit
• Clinical Significance: Increased side effect risk without additional efficacy
• Recommendation: AVOID concurrent use

3. Aromatase Inhibitors:

• Examples: Anastrozole, letrozole, exemestane
• Interaction: Additive effect on estradiol reduction
• Clinical Significance: May be beneficial in men with high estradiol on enclomiphene alone (off-label)
• Monitoring: Monitor estradiol; avoid excessive estradiol suppression (<10 pg/mL - may cause bone loss, joint pain)
• Recommendation: Use only under specialist guidance; monitor estradiol closely

4. Testosterone Replacement Therapy (TRT):

• Examples: Testosterone cypionate, enanthate, gel, pellets
• Interaction: TRT suppresses LH/FSH, counteracting enclomiphene's mechanism
• Clinical Significance: Concurrent use negates enclomiphene benefit
• Recommendation: AVOID concurrent use; choose one therapy or the other

5. Human Chorionic Gonadotropin (HCG):

• Interaction: Both stimulate testosterone production via different mechanisms (enclomiphene via endogenous LH; HCG as exogenous LH analog)
• Clinical Significance: Potentially synergistic but not systematically studied; may increase estradiol significantly
• Recommendation: Typically used separately; concurrent use requires specialist oversight

6. Gonadotropin-Releasing Hormone (GnRH) Agonists/Antagonists:

• Examples: Leuprolide, degarelix, relugolix
• Interaction: GnRH agonists/antagonists suppress LH/FSH, counteracting enclomiphene
• Clinical Significance: Concurrent use negates enclomiphene benefit
• Recommendation: AVOID concurrent use (GnRH agonists used for prostate cancer - contraindication for enclomiphene)

Cardiovascular Drug Interactions:

1. Anticoagulants:

• Examples: Warfarin, apixaban, ritonavir
• Interaction: SERMs may potentiate anticoagulant effects (theoretical; based on clomiphene data)
• Clinical Significance: Increased bleeding risk (rare)
• Monitoring: Monitor INR if on warfarin; no specific monitoring for DOACs
• Recommendation: Use with caution; inform prescribing physician

2. Antihypertensives:

• No significant interaction with enclomiphene
• Monitor blood pressure (testosterone increase may affect BP)

3. Statins:

• No significant interaction with enclomiphene
• Monitor lipid panel (enclomiphene may reduce HDL cholesterol)

Psychiatric Drug Interactions:

1. SSRIs/SNRIs:

• Interaction: CYP2D6 inhibition (see above)
• Clinical Significance: May increase enclomiphene levels
• Mood Effects: SSRIs may mitigate mood changes from enclomiphene (rare)
• Recommendation: Monitor for side effects; dose adjustment may be needed

2. MAO Inhibitors:

• No significant interaction reported
• Use with caution due to limited data

Herbal Supplements and Dietary Interactions:

1. St. John's Wort:

• Interaction: Strong CYP3A4 inducer
• Clinical Significance: Significantly reduces enclomiphene efficacy
• Recommendation: DISCONTINUE St. John's Wort before starting enclomiphene

2. Grapefruit Juice:

• Interaction: CYP3A4 inhibitor
• Clinical Significance: May increase enclomiphene levels
• Recommendation: AVOID grapefruit juice consumption while on enclomiphene

3. Saw Palmetto:

• No significant interaction
• May be used concurrently for benign prostatic hyperplasia (BPH)

4. Fenugreek, Tribulus Terrestris (Testosterone Boosters):

• No significant interaction
• Limited efficacy data for these supplements; additive benefit unclear

Food Interactions

Alcohol:

• No direct interaction with enclomiphene metabolism
• Excessive alcohol may worsen liver function (caution in hepatic impairment)
• Moderate alcohol consumption (1-2 drinks/day) acceptable

High-Fat Meals:

• No systematic food effect study
• Lipophilic drug; may have slightly better absorption with fatty meal (speculative)
• Recommendation: Take with or without food consistently

Laboratory Test Interactions

Testosterone Assays:

• Enclomiphene increases endogenous testosterone; no interference with testosterone assays
• Ensure lab uses accurate testosterone measurement (LC-MS/MS preferred over immunoassay)

Thyroid Function Tests:

• SERMs may increase thyroid-binding globulin (TBG), affecting total T4/T3 (not free T4/T3)
• Action: Monitor free T4 and TSH (unaffected by TBG)

Liver Function Tests:

• Enclomiphene does not interfere with AST/ALT/bilirubin assays

PSA:

• Testosterone increase may elevate PSA (physiologic response, not assay interference)

Pregnancy and Lactation (Not Applicable to Male Patients)

Pregnancy Category (If FDA-Approved):

• Expected Category: X (based on clomiphene classification)
• Rationale: Teratogenic in animal studies; not indicated in females
• Male Patients: No contraception required (enclomiphene does not affect partner pregnancy risk)

Lactation:

• Not applicable (male indication only)

Special Population Interactions

Pediatric (<18 years):

• Safety and efficacy not established
• Off-label use for delayed puberty (limited data)
• Drug interactions similar to adults

Geriatric (>65 years):

• No specific drug interactions
• Age-related hepatic function decline may increase enclomiphene exposure
• Monitor closely for side effects

Renal Impairment:

• Minimal renal excretion; no dose adjustment required
• No significant drug interactions related to renal function

Hepatic Impairment:

• Severe impairment: Contraindicated
• Mild-moderate impairment: Drug interactions with CYP inhibitors/inducers may be more pronounced

Summary Table: Key Drug Interactions

15. Goal Archetype Integration: Testosterone Optimization with Fertility Preservation

Primary Goal Archetype

Enclomiphene's Unique Position: Testosterone optimization WITHOUT fertility compromise.

This represents a distinct clinical niche where enclomiphene excels over all alternatives:

Ideal Candidate Profile for Enclomiphene

Primary Indicators:

1. Secondary hypogonadism with low testosterone (<300 ng/dL) but normal/low-normal LH (<8 IU/L)
2. Fertility concerns - actively trying to conceive OR desiring future fertility
3. Preference for oral therapy - avoids injections
4. Estradiol sensitivity - history of gynecomastia, mood changes with elevated E2, or baseline E2 >35 pg/mL

Supporting Indicators:

• Age 25-55 years (optimal response range)
• BMI <35 kg/m2 (higher BMI may need higher doses)
• No primary testicular failure (LH should NOT be elevated >12 IU/L)
• Reversibility desired - want option to discontinue therapy

Goal-Specific Clinical Pathways

Pathway 1: Active Fertility + Testosterone Optimization

• Scenario: Man with low testosterone AND actively trying to conceive
• Approach:
  1. Baseline labs: Total T, Free T, LH, FSH, E2, Prolactin, Semen Analysis
  2. Start enclomiphene 12.5 mg daily
  3. Recheck testosterone and semen analysis at 3 months
  4. Target: T >500 ng/dL, maintain or improve sperm parameters
• Duration: Continue throughout conception attempts; may continue indefinitely

Pathway 2: Future Fertility Preservation

• Scenario: Man with low testosterone who may want children in 3-10+ years
• Approach:
  1. Enclomiphene 12.5 mg daily (preserves testicular function)
  2. Annual semen analysis to confirm ongoing spermatogenesis
  3. Can transition to TRT later if fertility no longer a concern
• Advantage: Keeps options open; immediate fertility if circumstances change

Pathway 3: Transitioning from TRT

• Scenario: Man on TRT who now desires fertility
• Approach:
  1. Discontinue TRT
  2. Wait 4-6 weeks for testosterone to decline
  3. Start enclomiphene 12.5-25 mg daily
  4. Monitor testosterone recovery (may take 3-6 months for full axis recovery)
  5. Semen analysis at 3-6 months post-TRT
• Expected Timeline: HPG axis recovery typically 3-6 months; spermatogenesis recovery 6-12 months

16. Age-Stratified Dosing Protocol

Overview

Response to enclomiphene varies by age due to differences in HPG axis sensitivity, hepatic metabolism, and baseline hormonal status.

Age-Specific Dosing Recommendations

Ages 18-30 Years:

Ages 30-45 Years:

Ages 45-60 Years:

Ages >60 Years (Elderly):

Elderly-Specific Cautions (>60 Years):

• Hepatic Function: Age-related decline in CYP450 activity may increase drug exposure
• Cardiovascular Risk: Baseline ECG and cardiology clearance recommended
• Prostate Cancer Screening: PSA and DRE at baseline, 3 months, 6 months, then every 6 months
• Bone Health: Consider baseline DEXA; monitor bone density annually if prolonged use
• Polycythemia: Higher baseline hematocrit common; monitor CBC monthly for first 3 months
• Cognitive: Monitor for any cognitive changes (rare but report to provider)

Dose Reduction Considerations by Age

17. Clinical Decision Guide: Enclomiphene vs TRT vs Other Options

When to Choose Enclomiphene

Enclomiphene is the PREFERRED choice when:

1. Fertility is Important

   • Actively trying to conceive
   • May want children in the future (any age)
   • Partner has fertility issues requiring optimized male fertility
   • Sperm banking not performed before considering TRT

2. Secondary Hypogonadism Confirmed

   • Low testosterone (<300 ng/dL)
   • Normal or low LH (<8 IU/L) - indicates hypothalamic/pituitary origin
   • Testicular function preserved (testes respond to LH stimulation)

3. Estradiol Management Needed

   • Baseline estradiol elevated (>35 pg/mL)
   • History of gynecomastia or nipple tenderness
   • Mood symptoms with elevated estradiol
   • Prior poor response to clomiphene due to E2 elevation

4. Preference for Reversibility

   • Uncertain about long-term testosterone therapy
   • Want ability to stop and return to baseline quickly
   • Athletic considerations (though still WADA-prohibited)

5. Oral Route Preferred

   • Aversion to injections
   • Difficulty with topical compliance
   • Travel/lifestyle incompatible with injections

When to Choose TRT Instead

TRT (Testosterone Replacement) is PREFERRED when:

1. Primary Hypogonadism Present

   • Low testosterone with ELEVATED LH (>12 IU/L)
   • Testicular failure (testes cannot respond to LH stimulation)
   • Klinefelter syndrome, bilateral orchidectomy, testicular injury
   • Enclomiphene will NOT work - requires exogenous testosterone

2. Fertility is NOT a Concern

   • Completed family or no desire for biological children
   • Vasectomy performed
   • Willing to accept fertility suppression
   • Has banked sperm prior to TRT

3. Maximum Testosterone Response Needed

   • Severe symptoms requiring rapid, substantial testosterone increase
   • Inadequate response to enclomiphene (T remains <400 ng/dL on 25 mg)
   • Target testosterone >700 ng/dL for specific clinical indication

4. Cost Considerations

   • Generic TRT is significantly cheaper ($30-100/month vs $70-150/month)
   • Insurance more likely to cover FDA-approved TRT

When to Choose HCG

HCG may be preferred when:

1. Monotherapy Alternative to Enclomiphene

   • Oral compliance difficult
   • Failed enclomiphene trial
   • Prefer injection schedule (2-3x weekly)

2. Adjunct to TRT for Fertility

   • On TRT but fertility suddenly becomes important
   • Prevents complete testicular shutdown when added to TRT
   • Maintains spermatogenesis while on exogenous testosterone

3. Higher Testosterone Target with Fertility Preservation

   • May achieve slightly higher testosterone than enclomiphene
   • Accepts higher estradiol as trade-off

Combination Therapy Considerations

Enclomiphene + HCG:

• Generally NOT recommended - redundant mechanisms
• Both stimulate testosterone via different pathways
• May cause excessive estradiol elevation
• If used: Requires specialist oversight and close estradiol monitoring

Enclomiphene + TRT:

• CONTRAINDICATED - directly opposing mechanisms
• TRT suppresses LH, negating enclomiphene's mechanism
• Never use concurrently

Enclomiphene + Anastrozole:

• Generally NOT needed - enclomiphene already lowers estradiol
• Consider ONLY if estradiol remains >50 pg/mL despite enclomiphene
• Use lowest effective anastrozole dose (0.25 mg twice weekly)
• Risk of over-suppression of E2 (<10 pg/mL) causing bone loss, joint pain

Decision Algorithm

Step 1: Confirm Hypogonadism Type
├── LH Elevated (>12 IU/L) → PRIMARY Hypogonadism → TRT (enclomiphene ineffective)
└── LH Normal/Low (<8 IU/L) → SECONDARY Hypogonadism → Continue to Step 2

Step 2: Assess Fertility Status
├── Fertility Important (now or future) → ENCLOMIPHENE preferred
└── Fertility NOT Important → Continue to Step 3

Step 3: Assess Estradiol Profile
├── E2 Elevated or History of Gynecomastia → ENCLOMIPHENE preferred
└── E2 Normal, No Estrogen Sensitivity → Continue to Step 4

Step 4: Route of Administration Preference
├── Oral Preferred → ENCLOMIPHENE
├── Injection Acceptable → TRT or HCG
└── No Preference → Consider cost, insurance, testosterone target

Step 5: Final Decision
├── High Testosterone Target (>700 ng/dL needed) → TRT
├── Moderate Target (400-600 ng/dL), Oral → ENCLOMIPHENE
└── Moderate Target, Injection OK → TRT or HCG (cost consideration)

18. Enhanced Bloodwork Monitoring Protocol

Baseline Panel (Before Starting Enclomiphene)

Required Labs:

Conditional Labs:

6-8 Week Recheck (Initial Response Assessment)

Primary Purpose: Assess therapeutic response and titration needs

Required Labs:

Response Interpretation:

Goal Targets for Symptom Resolution

Target Lab Values on Therapy:

Long-Term Monitoring Schedule

Month 3:

• Full hormone panel (T, FT, E2, LH, FSH)
• CBC with hematocrit
• CMP (AST, ALT, Creatinine)
• Lipid panel
• PSA (if >40 years)

Month 6:

• Full hormone panel
• CBC
• CMP
• PSA (if >40 years)
• Clinical symptom assessment

Ongoing (Every 6 Months if Stable):

• Total Testosterone, Estradiol
• CBC with hematocrit
• CMP
• PSA (if >40 years)

Annual:

• Complete panel (all baseline labs)
• Semen analysis (if fertility monitoring)
• Clinical evaluation
• Cardiovascular risk assessment
• Consider DEXA (bone density) if >2 years on therapy

Troubleshooting Abnormal Lab Results

19. Specific Drug Interaction Guidance

Enclomiphene + TRT: Why They Should NOT Be Combined

Mechanism Conflict:

• Enclomiphene works by stimulating LH release from the pituitary
• TRT suppresses LH release (negative feedback)
• Combining them: TRT's suppressive effect negates enclomiphene entirely

Clinical Scenario: A patient on TRT with testicular atrophy wants to preserve testicular function. Adding enclomiphene while continuing TRT will NOT work.

Correct Approach:

1. If switching TO enclomiphene: Stop TRT, wait 4-6 weeks, then start enclomiphene
2. If wanting testicular support on TRT: Use HCG (not enclomiphene) as adjunct

Enclomiphene + Anastrozole: Usually NOT Needed

Why It's Usually Unnecessary:

• Enclomiphene ALREADY lowers estradiol (-5.92 pg/mL average)
• Adding anastrozole risks excessive E2 suppression (<10 pg/mL)
• Very low estradiol causes: bone loss, joint pain, cognitive issues, libido decrease

When Anastrozole MAY Be Considered:

If Using Both:

• Start anastrozole at lowest dose: 0.25 mg twice weekly
• Recheck estradiol in 4 weeks
• Target E2: 20-35 pg/mL (not lower)
• Symptoms of over-suppression: joint pain, low libido, fatigue, mood depression

Enclomiphene + HCG: Can Be Combined for Enhanced Effect

Mechanism:

• Enclomiphene: Stimulates endogenous LH release
• HCG: Acts as exogenous LH analog directly on testes
• Combined: Potentially additive testosterone stimulation

Clinical Considerations:

When Combination May Be Used:

1. Inadequate response to enclomiphene monotherapy (T <400 ng/dL on 25 mg)
2. Transitioning off TRT and need faster testicular recovery
3. Specialist oversight available for close monitoring

If Using Both:

• Enclomiphene: 12.5-25 mg daily
• HCG: 500-1000 IU twice weekly (lower dose than monotherapy)
• Monitor estradiol closely (may need anastrozole if E2 >50 pg/mL)
• Reassess need for combination at 3 months

Summary: Combination Therapy Quick Reference

Document Prepared By: Research Team, Epiq Aminos Last Updated: January 2025 Document Status: COMPLETE - Comprehensive Research Paper on Enclomiphene for Male Hypogonadism with Enhanced Clinical Decision Support